Company: BDRX
Filing Date: 2025-06-13
Form Type: 424B3
Source: 0001214659-25-009214
Chunk: 1

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-13
Form: 424B3
Chunk 1
---
-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form
40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

<div align='center'>Explanatory Note</div>

As previously disclosed,
on June 11, 2025, at a general meeting of Biodexa Pharmaceutical PLC (the “Company”) shareholders, the shareholders approved
new Articles of Association of the Company (the “New Articles”). The New Articles implemented the change in nominal value
of the Company’s ordinary shares, from £0.00005 per share to £0.000001 per share, that was also approved at the meeting.
A copy of the New Articles is attached hereto as Exhibit 1.1 and incorporated herein by reference.

The information included in this report on Form 6-K, including Exhibit 1.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-209365) and Form F-3 (File No. 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing
for the month of June 2025 is:

<div align='center'>SIGNATURE</div>

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|